Vascular Wall-Resident Multipotent Stem Cells within the Process of Vascular Remodelling by Klein, Diana
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Vascular Wall-Resident
Multipotent Stem Cells within
the Process of Vascular Remodelling
Diana  Klein
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/60561
Abstract
Processes of new vessel formation are central events in tissue development and repair.
Therein, sprouting endothelial cells and/or endothelial progenitor cells form imma‐
ture blood vessels that lack coverage by pericytes and other mural cells. Subsequently,
vascular remodelling takes place, in which association with mural cells (pericytes and
smooth muscle cells, SMC) stabilizes these immature vessels resulting in normaliza‐
tion of the vascular structures. Vascular remodelling is a dynamic and strictly
regulated process; an ordered remodelling seems to be critical for proper vascular
development, maintenance and stability of the vessel wall. The molecular and cellular
changes associated with this process and its importance for tumour growth remain
elusive. Up to now, the origin of vascular wall cells in tumours and the molecular
mechanisms that govern their recruitment and association with angiogenic endothe‐
lial cells (vascular stabilization) are not well understood. There is some evidence that
pericytes and SMC might originate from multipotent mesenchymal stem cells. This
chapter aims to explore the role of tissue-resident multipotent stem cells of mesen‐
chymal nature (VW-MPSCs) which putatively reside in the adventitia of adult blood
vessels within the process of vascular remodelling of tumour blood vessels as well as
of molecular factors that regulate VW-MPSC differentiation into pericytes and SMC.
Keywords: Vascular wall-resident multipotent stem cell, vascular remodelling, vascular stabili‐
zation, tumour vascularization, postnatal vasculogenesis
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1. Introduction
This chapter provides a summary of the current literature addressing the importance of
vascular wall-resident multipotent stem cells within the process of vascular remodelling. First,
the role of pericytes and smooth muscle cells (SMC) causing stabilization of angiogenic tumour
vessels will be discussed at the molecular and cellular level. This stabilization phase is crucial
for the survival of newly formed vessels, as immature vessels may rapidly become subject to
regression and cell death when the angiogenic stimulus is removed. The second part of the
chapter will focus on vascular wall-resident multipotent stem cells and evaluate the contribu‐
tion of circulating progenitor cells versus vessel-resident stem cells in the generation of
pericytes and SMC within the neovascularization process. Here, the hypothesis will be proved
that tissue-resident multipotent stem cells which putatively reside within the vascular
adventitia, rather than circulating multipotent stem cells, are the major source for pericytes
and SMC in the vascular stabilization processes. Finally, the regulation of differentiation of
vascular wall-resident multipotent stem cells into SMC will be discussed.
Aspects of vascular stabilization, e.g., some decisive factors for the mobilization of vessel-
resident stem cells and differentiation into pericytes and SMC, may have the potential for
clinically relevant applications in themselves. A better understanding of the molecular
processes in these cells could lead to the identification of new therapeutic targets.
2. Pericytes and smooth muscle cells cause a stabilization of newly formed
tumour vessels
Endothelia cover the innermost cell layer of the blood vessels. This continuous endothelium
is made impermeable for substances dissolved in the blood by the formation of tight junctions
in a first approximation. The necessary exchange of substances between blood and tissues is
tightly controlled by a highly selective transport mechanism [1]. The uncontrolled cell growth
which prevails in tumours results in a relative disparity between the tumour tissue and the
sufficient formation of vascular structures. The initiation of tumour angiogenesis is associated
with a structural destabilization of existing blood vessels. This causes an abnormally increased
vascular permeability, i.e., the existing endothelium is fenestrated, and endothelial cells lose
contact with one another and the underlying basal lamina. Finally, contact with the surround‐
ing mural, peri-endothelial cells (pericytes for capillaries and SMC of larger blood vessels) is
lost. This leads to the fact that the now mature and quiescent endothelial cells start to migrate
and proliferate [2-4]. During angiogenesis, continuous endothelial cells (the particularly
impermeable form of the endothelial cells) undergo phases where they are not continuous, so
are discontinuous (angiogenic endothelial cells). Chemotactic stimuli and vascular active
growth factors such as VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast
growth factor) secreted by tumour cells induce mobilization and migration of angiogenic
endothelial cells towards the tumour cells, which then build up new small blood vessels [5, 6].
During tumour angiogenesis, the hierarchical order of the blood vessels in large, medium and
small blood vessels that is found in normal vasculature is lost. New vessel formation in the
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tumour is disordered in structure; chaotic vascular structures are formed with areas of apparent
excess supply, in addition to areas with an undersupply of blood and in particular oxygen and
nutrition. In addition, tumour vessels have peculiarities in their structure: tumour vessels run
tortuously in the tissue, may end blindly (increased permeability of blood vessels), have arterio-
venous  shunts  (shorting  connections  causing  liquid  transfer  between  normally  separate
vessels), or be directed opposite to the blood flow (heterogeneous perfusion of the tumour
tissue). The endothelial lining is incomplete [4, 7, 8]. The newly formed vessel walls lack the
smooth muscle elements in their walls, so that they cannot actively respond to physiological
stimuli. For this reason, the newly formed angiogenic capillaries bear an increased risk of
rupture. Because of these features, tumour vessels prove to be functionally inferior. This
complicates the efficient administration of intravenous drugs in cancer therapy [9-12].
While angiogenesis describes new vessel formation by endothelial cells derived from pre-
existing vessels, postnatal vasculogenesis denotes vessel formation by assembly of endothelial
and/or vascular progenitor cells [13, 14]. Thus, the active cellular component in these processes
is granted by endothelial lineage cells, but neovascularization does not only depend on
endothelial cell migration and proliferation with subsequent formation of endothelial tubes;
it also requires pericyte coverage of vascular sprouts for vessel stabilization [15-18]. Thereby,
the vascular network can mature by recruitment of pericytes as well as SMC to stabilize the
immature tumour vessels (Figure 1).
Figure 1. Ultrastructural analysis of angiogenic tumour vessels. Subcutaneously grown B16F10 melanoma tumours
were removed 28 days after tumour induction and subjected to electron microscopic analysis. The presence of fenes‐
trae (emphasized by arrowheads) in angiogenic endothelial cells (EC) corroborate the less mature and functional inferi‐
or phenotype of these tumour vessels. Upon vessel maturation, these fenestrae disappear (upper panel). Vascular
remodelling can be further observed by association and integration of pericytes to the newly formed blood vessels,
resulting in vascular stabilization and thus maturation of angiogenic endothelial cells (lower panel). At the structural
level, the recruited pericytes are assembled into new capillaries and change cell morphology into a more flattened,
smooth muscle cell-like phenotype. In some tumour vessels, vascular mural cells seem to be more regularly integrated
into the wall of the new capillaries because of their tight contact with the endothelial cells, shown, for example, in their
sharing the same basement membrane, thereby indicating vessel stabilization and maturation (arrows). On PC peri‐
cyte: SMC smooth muscle cell, TC tumour cell, Lu lumen. Scale bar 1µm upper panel, 5µm lower panel.
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At the molecular level, for the expression of important signalling molecules or receptors,
or  cell  adhesion  molecules,  there  is  a  locally  pronounced  heterogeneity  in  the  tumour
vascular bed [19, 20]. For a long time, these findings were interpreted as if there were no
restructuring processes (vascular remodelling) of newly formed blood vessels in terms of
a re-stabilization in the tumour vascular bed.  Recent findings,  however,  show that even
tumour  vessels  undergo  a  reorganization  in  terms  of  vascular  stabilization  to  a  certain
degree [21, 22]. Electron microscopy analyses indicate that partially stabilized blood vessels
exist  that  differ  in  their  architecture  from  the  usual  blood  vessels  next  to  structurally
stabilized  and  mature  blood  vessels,  so  that  angiogenic  and  less  stabilized  vessels  are
disordered and regarded as immature. In combination with the fact that tumours require
blood vessels for progressive tumour growth, many new cancer therapies directed against
the tumour vasculature (anti-vascular agents, anti-angiogenic agents) have been investigat‐
ed. It was thought that these anti-angiogenic therapies could destroy the tumour vascula‐
ture to deprive the tumour of oxygen and nutrients.  By contrast,  it  was shown that the
process of vascular remodelling in tumours was affected during treatment with angiogen‐
esis inhibitors [18, 23-26]. Besides a dramatic tumour regression observed some angiogen‐
esis  inhibitors,  the  tumours  also  became resistant  to  prolonged anti-angiogenic  therapy.
The  tumour  regression  was  histological,  revealing  a  reduction  in  tumour  vascularity
observed during treatment predominantly as a result of the loss of less mature and highly
proliferative small-calibre vessels. The remaining vessels were characterized by an increase
in vessel diameter, and by the association and integration of pericytes and SMC leading
to  vascular  stabilization in  terms of  vessel  maturation,  and thus  a  normalization of  the
vascular. This finally leads to an alternative hypothesis, that certain anti-angiogenic agents
can  also  transiently  normalize  the  abnormal  structure  and  function  of  tumour  vascula‐
ture to make it  more efficient  for  oxygen and drug delivery [26].  Meanwhile,  an exten‐
sive arsenal of anti-angiogenic compounds is available, and their effectiveness is currently
being tested in numerous clinical studies. Bevacizumab is a humanized monoclonal anti-
VEGF antibody which neutralizes any VEGF isoforms and prevents the interaction of VEGF
with the corresponding receptors [27-29]. Clinical trials with bevacizumab show synergis‐
tic  anti-tumour  and chemotherapeutic  effects.  The  results  of  histological  examination  of
tumour tissue in clinical  trials  with anti-angiogenic substances showed a stabilization of
tumour vessels, which was associated with a reduction in vascular density in the tumour
tissue [11, 30-32].
In general, bevacizumab is used as first-line drug in combination with conventional chemo‐
therapeutics in patients with metastatic colorectal cancer, unless contra-indicated. The
continuation of bevacizumab beyond first-line progression is still controversial, due to a lack
of prospective randomized evidence in this setting [33]. The clinical efficacy of angiogenesis
inhibitors targeting vascular endothelial cells has not been as successful as initially hoped, and
improved clinical outcomes have been observed in combination with chemotherapy or
additional drugs for many types of human cancer. This may be at least partially due to the fact
that anti-angiogenic therapy triggers vascular stabilization including pericyte coverage, and
that pericyte coverage further impairs tumour vessel regression in response to anti-angiogenic
treatment [34]. Furthermore, tumour vessels which are resistant to anti-angiogenic therapy are
characterized by an increase in vessel diameter and a normalization of vascular structures.
Muscle Cell and Tissue30
This normalization is achieved by the recruitment and integration of mature pericytes in the
vessel wall for capillaries as well as SMC for larger vessels (Figure 2). This process is accelerated
in tumour therapy when agents that affect the formation of new vessels (anti-angiogenic
agents) were applied [11]. In contrast, the presence of VEGF led to ablation of pericyte coverage
on nascent vascular sprouts and vessel destabilization [35]. Thus, targeting pericyte recruit‐
ment, coverage and function in addition to endothelial cells may be suitable for promoting
progress in anti-angiogenic tumour therapy [36, 37]. In addition, the use of angiogenesis
inhibitors which lead to a normalization of tumour vessels in combination with conventional
therapies such as radiation or chemotherapy should lead to enhanced efficacy of drug delivery
and diminished toxicity [38-40].
3. Vascular wall-resident multipotent stem cells stabilize angiogenic
tumour blood vessels by differentiation into pericytes and smooth muscle
cells
Until some years ago, the bone marrow and endothelial cell compartment lining the vessel
lumen (sub-endothelial space) were thought to be the only sources providing vascular
Figure 2. Scheme of the extensive remodelling of the tumour vascular bed by a partial structural stabilization of
blood vessels upon tumour progression. Newly formed tumour vessels supply a highly dense network of immature
and unstable vessels. Upon tumour progression, angiogenic vessels can mature by the association and integration of
pericytes and smooth muscle cells preferentially in the tumour centre zone. This process is accelerated in tumour ther‐
apy when anti-angiogenic agents are applied. Further vessel maturation leads to vessels characterized by an increased
diameter, a reduction of vascular density and mural cell integration, resulting in normalization of the vascular bed.
This process is accompanied by an extensive necrosis of the neighbouring tumour areas while viable tumour cell rows
are circularly arranged around stabilized large arteries.
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progenitor cells. Results published recently have identified the human vessel wall as a niche
for stem cells [41-44]. Herein, the blood vessels themselves harbour progenitors and multipo‐
tent stem cells (vascular wall-resident EPCs, VW-EPCs and haematopoietic stem cells, HPCs),
clearly indicating the presence of stem cell niches outside the bone marrow and the peripheral
blood [45-48]. Arterial vessels have what is termed an adventitial regeneration zone, in which
those various stem and progenitor cells reside (Figure 3). These cells are able to form vascular
networks and are capable of differentiating into endothelial cells and CD68+ macrophages [43,
46, 49]. However, the blood vessel wall is made not only of endothelial but also peri-endothelial
cells (pericytes/SMC) and adventitial cells. Thus, the adequate formation of new blood vessels
under hypoxia, during ischaemia or in tumour neovascularization, depends on the presence
and recruitment of these peri-endothelial in addition to endothelial cells. Accordingly, the stem
cell niche “vasculogenic zone” also harbours mesenchymal stem cells (MSCs) [43, 46].
Pericytes play a central role in tumour angiogenesis and these cells significantly affect the
success of anti-angiogenic therapies. Thus it is important to identify pericytes in different
tumour entities [50, 51]. In capillaries, pericytes are in close contact with endothelial cells and
share the same capillary basement membrane. Pericytes express alpha-smooth muscle actin
(ACTA2) and thus they might have contractile properties. However, the origins of pericytes
and of SMC in tumours, and the molecular mechanisms that govern their recruitment and
association with tumour vessels, are not clear. Endothelial expression of the platelet-derived
growth factor B (PDGF-B) was shown to trigger the recruitment of pericytes necessary for the
remodelling of newly formed vessels in terms of vascular stabilization, so that immature
vessels with or without pericytes are formed [52]. Using an 'in vitro angiogenesis’ system,
Nicosia and co-workers suggested that pericytes are formed by migration and de-differentia‐
tion of arterial SMC [53]. Interestingly, pericytes have been assumed to differentiate in situ
from mesenchymal cells [54]. In line with the idea that pericytes might have their origin in
MSCs, it has been shown that Sca-1-positive bone marrow (BM)-derived cells are recruited to
the site of tumour progression using the RIP-Tag2 model of pancreatic cancer [55].
In line with these findings, several studies identified human vascular wall-resident CD44+
multipotent stem cells (VW-MPSCs) within the adult human vascular adventitia which were
capable of differentiation into pericytes and SMC [45, 46, 56-59]. VW-MPSCs were shown to
contribute to in vivo vessel morphogenesis by co-implantation of isolated VW-MPSCs and
human umbilical cord vein endothelial cell (HUVEC) in a matrigel plug assay [46]. Within the
plugs, implanted HUVEC formed blood perfused vessels. Co-implanted VW-MPSCs assem‐
bled at the new vessels and were differentiated into transgelin-positive/ACTA2-positive SMC/
pericytes, undoubtedly confirming that VW-MPSCs have the capability to differentiate into
pericyte/SMC and thus contribute to morphogenesis of new vessels under in vivo conditions.
Electron microscopic analysis further demonstrated at the ultrastructural level that VW-
MPSCs were not only aligned to new capillaries but were also regularly integrated into the
wall of new capillaries; for example, EC and pericytes are enclosed by the same basal lamina.
Thus, a crucial hypothesis concerning the vessel-resident stem cells is that these cells are the
"first-line" cells, which are available on the basis of their anatomic location as the first point of
contact for tumour cells and for tumour cell-secreted factors [43, 46, 60, 61]. Moreover, it is
hypothesized that MPSCs or smooth muscle progenitors, resident in the vessel wall, would
serve as a source for local recruitment of cells to stabilize new immature vessels constructed
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only by endothelial cells. Under vascular restructuring processes (remodelling) these VW-
MPSCs associate with the newly formed blood vessels of the tumour and differentiate into
pericytes and SMC, which results in a stabilization of the newly formed vessels (Figure 3).
Figure 3. Vascular remodelling. New vessel formation by both angiogenesis and postnatal vasculogenesis is a prereq‐
uisite for tissue regeneration and several diseases including tumour progression and atherosclerosis. Vascular stabili‐
zation is achieved by the recruitment and integration of mature pericytes in the vessel wall for capillaries, as well as
smooth muscle cells (SMC) for larger vessels. Intima, media (TM) and adventitia with vasa vasorum (VV) are fixed
layers of the wall of large arteries and veins. The border between media and adventitia is marked by outer elastic
membrane (green). The vasculogenic zone is a vascular mural zone located within the adventitia and close to the tuni‐
ca media which harbours different subsets of vascular wall stem cells. The central hypothesis concerning vascular
wall-resident multipotent MSCs (VW-MPSC) is that these cells serve as major source for pericytes and SMC for stabili‐
zation of new vessels, or repair of pre-existing vessels under physiological conditions. Localized within the vascular
adventitia, which serves as an interface between the inner parts of the vessel wall, including blood flow and the sur‐
rounding tissue, the VW-MPSCs might serve as an important therapeutic target. Under vascular restructuring process‐
es (remodelling), these MSCs associate with the newly formed blood vessels of the tumour and differentiate into
pericytes and SMC, which results in a stabilization and thus normalization of angiogenic tumour blood vessels. VW-
MPSCs’ differentiation into SMC may be induced by tumours, inflammation and hypoxia in tissue areas around blood
vessels, contributing to morphogenesis of new vessel walls (e.g., tumour vascularization, intimal lesions or neointima
formation). In contrast to the direct action of MPSCs during tumour progression through becoming mobilized from
their niche and subsequently differentiated at the site of injury, the protective effect of endogenous or exogenous ap‐
plied MSCs could also be related to the modulation of paracrine characteristics of these cells. HSP, haematopoietic
stem cell; EPC, endothelial progenitor cell; PC, pericyte; yellow, endothelial cells; green basement membrane and elas‐
tic membrane; blue, SMC.
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Multipotent MSCs were intensively analysed using in vitro studies: optimized conditions were
identified for their expansion and potential for differentiation along mesodermal lineages, e.g.,
into bone, fat, muscle and cartilage [62-65]. A frequently used source of MSCs is the bone
marrow [66]. Here, only 0.01 to 0.001 % of the mononuclear cells in the BM are MSCs. Fur‐
thermore, human MSCs (hMSCs) can be obtained from umbilical cord blood, placental blood,
foetal liver and adipose tissue [67-71]. It is further hypothesized that so-called permanent tissue
stem cells exist in virtually every tissue type [72, 73]. In view of the fact that the blood vessels’
area is a common structure of all tissues and organs, it is obvious that vessel-resident stem and
progenitor cells may have great potential in biomedicine [46, 59, 74-76]. Together with the fact
that tissue-specific stem cells differentiate predominantly into the tissue type from which they
derive, vessel-resident (multipotent) MSCs may be particularly well suited to contribute to the
formation of new vessels.
In general, abnormal vasculature is a hallmark of solid tumours. The exact quantification of
tumour vessels is useful to evaluate prognosis, because the degree of angiogenesis is associated
with tumour aggressiveness and clinical outcome [77]. Together with the fact that pericytes
and SMC play a central role in vascular remodelling of tumour vessels, their recruitment and
stable integration into stabilized tumour vessels may determine the success of anti-angiogenic
therapies [78, 79]. Accordingly, future therapies targeting both endothelium and pericytes may
favour progress in anti-angiogenic treatment for malignant tumours [80]. Thus, it is important
to identify the origin and localization of pericytes and SMC in tumour tissues from cancer
patients to gain a better understanding of their role in tumour growth and metastasis as well
as to improve the outcome of anticancer therapies. Concerning the hypothesis that multipotent
stem cells of mesenchymal nature (MPSCs) which express the (neural) stem cell marker nestin
are the major source for pericytes and SMC in vascular stabilization processes, nestin-GFP
transgenic mice were used in order to track MPSCs’ contribution to the vascular remodelling
processes. Nestin-GFP transgenic mice express GFP under the regulatory elements of the
nestin promoter [81]. For transgene construction, the second intron of nestin gene was utilized,
which was known to drive the expression in neural stem and progenitor cells. Furthermore,
the 5′ upstream region (promoter region) in the transgene construct was included, the
regulatory function of which is still unclear [82, 83]. Thus, these mice were ideally suited for
the evaluation of the role of nestin-positive cells during the vascular remodelling of tumour
blood vessels (Figure 4). Besides this, the BM tissue-resident nestin-GFP-positive cells are
localized in the wall of mouse aortas and express nestin while lacking CD34 expression. Using
arterial slice cultures of ex vivo isolates, these cells can be mobilized from their niche by factors
secreted from cultured tumour cell lines, and are capable of differentiating into pericytes and
SMC. In line with these results, Lin et al. have shown that tissue-resident MPSCs isolated from
different anatomic locations gain the capacity to modulate the formation of vasculature by
tightly surrounding newly formed microvessels as perivascular cells using a matrigel plug
assay [84]. Furthermore, it has been demonstrated that human MPSCs derived either from the
vascular adventitia or the bone marrow efficiently stabilized nascent blood vessels in vitro by
functioning as perivascular precursor cells [46, 85]. Furthermore, vascular wall-resident nestin-
GFP-positive cells can be isolated and cultivated. Primary cell cultures exhibited typical MSC
characteristics. According to the guidelines, clonally expanded cells adhered on plastic,
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differentiated into adipocytes, chondrocytes and osteocytes under certain cell culture condi‐
tions [86]. These findings are in line with previous reports. Recently it has been elegantly
demonstrated that nestin-GFP-positive cells in the BM are enriched in mesenchymal stem cell
activities and are pericyte-like [87].
Figure 4. Nestin-GFP(+) multipotent cells are localized in the vasculogenic zone of murine aorta. (A) Immunohisto‐
logical analysis of stem cell antigen-1 (Sca-1) expression in mouse aorta sections. Scale bar 100µm. (B) Immunofluores‐
cence analysis of nestin-GFP-positive MSCs in their native niche was performed using double immunostainings on
mouse aorta sections combining antibodies against GFP (green) and SMA or CD34 (red). Dotted line marks the border
between media and adventitia of the aortic wall. Scale bar 20µm. (C) Electron microscopic analysis indicates the pres‐
ence of undifferentiated cells (putative stem cells (pSC) in the vasculogenic zone (Ad) of the adventitia. eEM external
elastic membrane, SMC smooth muscle cell, TM, tunica media, Coll collagen.
In order to determine the contribution of the tissue-resident MPSCs to the formation of tumour
neovasculature, BM transplantation experiments were performed. Tissue-derived cells were
tracked when wild-type BM cells were isolated from C57BL/6 mice and transplanted into
lethally irradiated, age-matched, syngeneic, nestin-GFP transgenic recipients [81]. Tumours
grown in reconstituted nestin-GFP transgenic mice which received wild-type BM showed that
ACTA2-positive pericytes exclusively expressed GFP, demonstrating that nestin-GFP-positive
pericytes derived from tissue-resident cells and not circulating (BM-derived) MSCs stabilize
angiogenic vessels in tumours grown in those mice. In combination with intensive immuno‐
fluorescence analysis, these results strongly confirmed the hypothesis that nestin-GFP-positive
MSCs are apparently involved directly in vascular remodelling processes in terms of vascular
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stabilization, serving as a major source for pericytes and SMC. Thus, vascular wall-resident
MSCs have to be considered in future strategies for anti-angiogenic tumour therapy. According
to this idea, nestin expression of human colorectal adenocarcinoma metastases under clinical
treatment with bevacizumab showed a prominent stabilization of tumour vessels by increased
integration of nestin-positive pericytes and/or SMC into the vessel wall [81]. Mature vessels
from the tumour’s surrounding area or healthy tissue, by contrast, down-regulated nestin
expression. Nestin expression had already been considered to be specific for developing
vascular smooth muscle cells (VSMC), whereas differentiated, postmitotic VSMC were
negative for nestin [88]. Conclusively, nestin-targeted therapy may suppress tumour prolif‐
eration via inhibition of neovascularization and vessel stabilization in numerous malignancies,
including colorectal cancer and melanomas. Nestin, an intermediate filament protein, is
reportedly expressed in repair processes, various neoplasms, and proliferating vascular
endothelial cells [89, 90]. It was recently reported to be expressed in proliferating endothelial
progenitor cells, but not in mature endothelial cells. Tumour endothelium-specific expression
is thought to depend on the first intron of the nestin gene, whereas neural stem cell-specific
and thus MSC-specific expression is usually regulated by the second intron [90]. Therefore,
expression of nestin was described to be relatively limited in proliferating vascular endothelial
cells and EPCs. Using another but similarly constructed nestin-GFP plasmid generated nestin-
GFP transgenic mouse, nestin-positive pericytes have been identified as the progenitors of all
Leydig cell phenotypes, indicating that vascular cell types, acting like adult stem cells, play a
critical role in organ formation [91]. Thus, these findings confirm the idea that addressing
pericytes, in particular by nestin-targeted therapy, may be suitable to selectively address newly
formed and partially stabilized tumour blood vessels.
From the literature,  it  appears to still  be controversial  whether and to what extent  BM-
derived vascular progenitor cells or tissue-resident stem and progenitor cells contribute to
neovascularization processes. BM-derived endothelial progenitor cells (BM-EPCs) have been
shown to represent an alternative source of endothelial cells for adult neovascularization
in the process defined as postnatal vasculogenesis [92, 93]. Thus, BM-EPCs might consti‐
tute  a  new  and  promising  target  for  pro-  or  anti-angiogenic  treatment  strategies  [94].
However, there is extensive variation about their contribution to tumour neovasculariza‐
tion of  primary tumours,  and the  respective  values  range from 50 % incorporated BM-
EPCs to undetectable numbers, demonstrating that the exact role of these cells in postnatal
vasculogenesis  is  not  quite  clear  [95-97].  These  contradictory results  may be  due to  the
methodological  difficulties in distinguishing BM-derived cells  from intimately associated
cells  [94].  Furthermore,  the  effects  of  MSCs  on  tumour  growth  are  still  controversial.
Interactions between MSCs and tumour cells might play an important role in tumour growth
[98, 99]. Herein, MSCs have been shown to transmit their tumour-promoting activity via a
paracrine  mechanism  of  action:  conditioned  media  derived  from  cultured  BM-MSCs
induced the expression of VEGF in tumour cells  as well  as the activation RhoA-GTPase
and ERK1/2 [100]. Furthermore, BM-derived MSCs (also called mesenchymal stromal cells)
have  been  reported  to  migrate  to  the  site  of  tumour  progression  and  to  subsequently
differentiate  into  carcinoma-associated  fibroblast  (CAF)-like  cells,  thereby  representing
tumour-promoting stromal cells. As CAFs express platelet-derived growth factor receptor
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(PDGFR) at a high level, a blockade of PDGF signalling pathways by imatinib treatment
influenced  the  interaction  between  BM-derived  MSCs  and  tumour  cells  in  the  tumour
microenvironment and, hence, inhibited the progressive growth of colon cancer [101].
In general, considerable evidence is accumulating for the involvement of tissue-resident and
in particular vessel-associated MPSCs in regenerative and pathological adult neovasculariza‐
tion [43, 102, 103]. In vitro experiments further suggested that proliferative SMCs are derived
from the differentiation of multipotent vascular stem cell (MVSC) of the blood vessel wall
instead of the de-differentiation of mature SMCs [104]. MVSCs-expressed markers including
Sox17, Sox10 and S100β were cloneable, had telomerase activity, and differentiated into neural
cells and mesenchymal stem cell (MSC)-like cells that subsequently differentiated into SMCs.
In vivo experiments further demonstrated that MVSCs, rather than mature SMCs, repopulate
the tunica media and form neointima after endothelial denudation injury [104]. Whether
MVSCs were derived from the de-differentiation of mature SMCs was determined by lineage
tracing using SM-MHC as a marker in SM-MHC-Cre/LoxP-enhanced green fluorescence
protein (EGFP) mice [105, 106]. These studies support the hypothesis that vascular multipotent
stem cells of a mesenchymal nature were activated and generated SMC by differentiation
instead of a possible SMC de-differentiation of the vascular wall. We may conclude that, in
addition to their above-described role in tumour vascularization, the aberrant activation and
differentiation of vascular wall-resident multipotent stem cells may contribute the develop‐
ment of vascular diseases. These findings may have a transformative impact on vascular
biology, vascular diseases and remodelling, and may lead to new therapies by using VW-
MPSCs as a therapeutic target.
4. Regulation of differentiation of vascular wall-resident multipotent stem
cells into smooth muscle cells
Epigenetic regulation was shown to play a crucial role in SMC differentiation [107]. High levels
of histone modifications were found in promoters of SMC-specific genes as compared to
undifferentiated embryonic stem cells [108, 109]. Of the epigenetic regulation mechanisms,
histone acetylation, which is adjusted through acetyltransferases (HATs) and histone deace‐
tylases (HDACs), primarily promotes the expression of target genes [110]. However, whether
the differentiation of MSCs to SMCs was affected by such histone modifications remains
unresolved. HDACs, however, can arrest stem cell proliferation and induce cell differentiation
and apoptosis [111]. A histone deacetylase inhibitor (sodium butyrate) was further found to
effectively promote rat BM-MSC differentiation into SMCs; a strategy that could potentially
be applied in clinical tissue engineering and cell transplantation, for example for the treatment
of bladder function disorders such as stress urinary incontinence [112, 113].
In order to  identify molecular  mechanisms governing the differentiation of  the vascular
wall-resident MPSCs into SMCs, cDNA microarray analyses on MPSCs isolated from human
internal  thoracic  artery  fragments  in  comparison  to  mature  SMC  of  human  aorta  were
performed (unpublished data). Among several genes being differentially expressed in VW-
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MPSCs, the HOX genes HOXB7, HOXC6 and HOXC8 were found to be expressed in VW-
MPSCs at a clearly higher level than in mature hAoSMC [60]. The HOX genes are a family
of regulatory transcription factors that control the activity of other functionally related genes
in the course of individual development, and are expressed variously in the adult organ‐
ism [114]. Because of their central role in the development of body parts, limbs and organs,
mutation of these genes can cause serious changes in body parts at points in the body that
they do not physiologically occur, such as the conversion of complete limbs. In humans,
so  far,  HOX-39  transcription  factors  have  been  identified  in  the  four  separate  clusters
(HOXA-D) that are located on four different chromosomes. Together with accessory factors,
HOX proteins bind to specific DNA sequences in order to activate or repress genes [115].
HOX  genes  are  thought  to  act  as  micromanagers  orchestrating  cell  differentiation  after
embryonic development in many different cell types and developmental pathways [116].
In the adult, it is already known that colony-forming unit-fibroblasts (CFU-F) derived from
different organs have characteristic HOX expression signatures that are heterogeneous but
highly specific for their anatomical origin [117]. The topographic specificity of HOX code
is maintained during differentiation, which indeed suggests that the pattern of expression
is an intrinsic property of MSCs. Furthermore,  stem and progenitor cells  from mesoder‐
mal  tissues  have HOX-specific  gene expression profiles.  This  so-called biological  finger‐
print can be used to differentiate functionally different MSC populations from bone marrow
and umbilical cord blood [118]. Thus, HOX proteins have a role in specifying the cellular
identity of MSC. A differential analysis of 39 HOX genes in vascular wall-resident MPSCs
compared  to  terminally  differentiated  endothelial  cells,  SMC  and  less  differentiated
(pluripotent) embryonic stem cells showed that HOX family members HOXB7, HOXC6 and
HOXC8 are  overexpressed  in  the  vessel-resident  MPSCs.  This  suggests  that  these  HOX
genes are involved in the development and differentiation of the VW-MPSCs [60]. To gain
further insights into the molecular role of these HOX genes for VW-MPSC differentiation
as well as to identify potential downstream regulated genes of HOXB7, HOXC6 and HOXC8
activity, VW-MPSCs were transfected with HOXB7, HOXC6 and HOXC8-specific siRNAs
both  individually  and  in  defined  combinations  using  non-specific  siRNAs  as  controls.
Interestingly, silencing these HOX genes in VW-MPSCs significantly reduced their sprout‐
ing capacity and increased expression of the SMC differentiation and maturation markers
transgelin  (TAGLN)  and  calponin  (CNN1),  and  the  histone  gene  histone  H1.  Further‐
more,  the methylation pattern of  the TAGLN promoter  was altered,  which clearly indi‐
cates  a  differentiation  of  VW-MPSCs  to  a  more  mature  SMC  phenotype.  A  restricted
expression of HOX genes, in particular HOXB7, had already been reported in the 1990s to
distinguish foetal  from adult  human SMC, whereby HOXB7 was expressed at  markedly
higher levels in embryonic vascular SMC as compared to mature SMC of adult vessels [119].
These data suggest that HOXB7 initiates a differentiation from multipotent cell type towards
SMC, but stops the further differentiation of these cells  into mature SMC. Further strik‐
ing evidence is that H1 is also involved in the regulation of VW-MPSC differentiation into
SMC  [60].  H1  expression  in  VW-MPSCs  is  significantly  enhanced  upon  differentiation
towards SMC, as shown after gene silencing for HOXB7, HOXC6 and HOXC8, respective‐
ly. In general, H1 function can alter the chromatin structure and serves as both a positive
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and negative regulator of transcription, depending on the gene. H1 can further influence
DNA methylation and regulate specific gene expression [120-122]. We may conclude that
the interaction of  H1 and HOXB7 might  be a  more specific  mechanism regulating gene
expression  and  differentiation  of  VW-MPSCs  to  SMCs  and  then  to  mature  SMCs  in
physiological  remodelling processes  of  the vessel  wall  and vascular  diseases.  Indeed,  in
human atherosclerotic  lesions,  where mature SMCs revert  to  a  more immature and less
contractile phenotype, HOXB7 mRNA was detected at a higher level than in normal artery
wall  [123].  An even closer  relationship  seems to  exist  between VW-MPSCs and mature
SMCs.  SMC  differentiation  is  accompanied  by  enhanced  ACTA2,  TAGLN  and  CNN1
expression. TAGLN is expressed exclusively in smooth muscle-containing tissues of adult
mammals,  and  is  one  of  the  earliest  markers  of  differentiating  SMCs  [124].  While  the
expression of these markers is  a common feature of SMC regardless of  their  anatomical
position, it has been shown that even SMCs of different parts of adult arteries, e.g., aortic
arch,  abdominal  aorta  and femoral  artery,  exhibit  different  codes  of  HOX gene  expres‐
sion, indicating the close relation between HOX code and the anatomical positional identity
of SMC in each part of the blood vessels [125].
Further candidate factors were reported to be important for MSC differentiation to SMC. The
most prominent one is the morphogenetic transforming growth factor-beta (TGFb) [126]. TGFb
stimulation alone is sufficient for the induction of a rapid SMC differentiation of MPSC and
MSC-like cells [46, 127, 128]. Isolated VW-MPSCs exposed to exogenous TGFβ1 during
culturing exhibited alterations in the gene expression profile in the form of significantly
increased expression of the SMC markers TAGLN, hyaluronan and proteoglycan binding link
protein (HAPLN), and thrombospondin 1 (THSP1) [46]. In embryonic stem cell-derived MSCs
(hES-MCs), TGF-β-treatment resulted in SMC differentiation in a dose- and time-dependent
manner as demonstrated by the expression of SMC-specific genes ACTA2, CNN1, and smooth
muscle myosin heavy chain (SM-MHC) [127]. Mechanistically, TGFb-induced differentiation
was Smad- and serum response factor/myocardin-dependent. Furthermore, the treatment of
adipose tissue-derived MSCs (hASCs) with TGFb dramatically increased the contraction of a
collagen-gel lattice and the expression levels of SMC-specific genes including ACTA2, CNN1,
SM-MHC, smoothelin-B, myocardin and h-caldesmon, as well as causing an increased
expression of vascular SMC-like ion channels, indicating differentiation of hASCs into
contractile vascular SMCs [128]. Beside the direct action of growth and differentiation factors,
either by direct, exogenous application to cultured MPSC and MSC-like cells, or by stimulation
of vascular MPSC in their native niche (e.g., by tumour secretion), other factors were described
as decisive for the SMC differentiation of vascular multipotent stem cells. The differential
expression of these cell-type-specific factors seems to act more indirectly, and to prime the cell
somehow to differentiate along the SMC lineage. The basic molecular mechanism behind these
cell-type-specific factors remains elusive at present. A prominent EphA3 expression in
endometrial spiral arterioles and surrounding stroma, but not in other human tissues, suggests
EphA3 as a unique marker of perivascular MSCs that are implicated in rapid neovasculariza‐
tion and vascular remodelling [129]. This selective EphA3 expression was further observed in
actively growing rather than established blood vessels in the vascular microenvironment of
solid tumours. In addition, a strong expression of CD146 within a BM-MSC subpopulation
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was associated with a commitment to a vascular smooth muscle cell lineage characterized by
a strong up-regulation of calponin-1 and SM22α expression and an ability to contract the
collagen matrix [130].
5. Concluding remarks
Angiogenesis and vasculogenesis are central events in tissue development and repair. Initially,
sprouting endothelial cells form immature blood vessels that lack coverage by pericytes and
other mural cells. Subsequently vascular remodelling takes place, in which association with
mural cells (pericytes and SMC) stabilizes these immature vessels. Vascular remodelling is a
dynamic and strictly regulated process, which is active in a variety of physiological processes,
such as vessel growth, angiogenesis and wound healing. An ordered remodelling seems to be
critical for proper vascular development and maintenance and is an absolute prerequisite to
preserve the sensitive relationship between resilience and stability of the vessel wall. However,
remodelling is also initiated during pathological processes, such as atherosclerosis, ischaemia,
congenital vascular lesions, vasculotoxic therapies and tumour growth.
Organ-specific multipotent stem cell types are associated with the vessel wall, in particular
within the so-called “vasculogenic zone” of the vascular adventitia. These findings together
with the stem cell-supporting functions of endothelial cells suggest that the vascular wall
provides niches for different somatic stem cell types within the sub-endothelial space and the
vascular adventitia. It conformity with the niche function of the adventitial vasculogenic zone,
the presence of Sca-1+ smooth muscle cell progenitors has been shown within this zone [131].
Furthermore, it was reported that a subset of CD34+ cells within the vascular adventitia has
the capacity to differentiate into pericytes [132]. More recently,
CD44(+)CD90(+)CD73(+)CD34(-)CD45(-) cells were identified within the adult human arterial
adventitia, which were termed vascular wall-resident multipotent stem cells (VW-MPSCs) and
were capable of differentiating into vascular SMC and pericytes under in vitro and in vivo
conditions [46]. These cells reside predominantly in the vasculogenic zone of adult human
blood vessels and contribute to maturation of newly formed vessels.
In general, tissue-specific stem cells differentiate mainly to the type of tissue from which they
derive, indicating that there might be a certain code (“priming”) within the cells determined
by the tissue of origin. Furthermore, due to their anatomical localization it is believed the
vessel-resident stem and progenitor cells are available as a first point of contact for the secreted
factors from tumour cells (Figure 5). Without mobilization from the niche, VW-MPSCs express
HOXB7, HOXC6 and HOXC8 at higher levels as compared to SMCs. These HOX genes
suppress the expression of TAGLN and CNN1 in VW-MPSCs, essential factors of early SMC
differentiation. This mechanism probably accounts for keeping the VW-MPSCs quiescent in
the adventitial niche. In contrast, silencing of HOX genes alter the CpG methylation of TAGLN
promotor resulted in increased TAGLN expression which induced VW-MPSC differentiation
into SMC/pericytes [60]. Thus, as discussed here in detail, VW-MPSCs are directly involved in
vascular remodelling processes as these cells represent the major source of pericytes and SMC
during angiogenesis and vascular stabilization processes under physiological and pathological
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conditions. Therefore, these cells may be a promising target for counteracting vascular
remodelling and related anti-angiogenic drug resistance.
In future investigations, a detailed molecular analysis of vascular wall-resident multipotent
stem cells and of their differentiation into pericytes in response to tumour-secreted factors may
be decisive to gain a better understanding of MPSC biology and differentiation. Particularly
for cancer therapy, there is an urgent need to identify signalling molecules that are selectively
regulated during the process of new vessel formation and/or subsequent vascular stabilization.
Targeting of such molecules might also help to minimize anti-angiogenic drug resistance due
to vascular stabilization. These investigations will provide basic knowledge for the design of
innovative therapeutic strategies that target those vascular remodelling processes during
cancer treatment that are associated with worse prognosis, for example, the generation of drug-
resistant tumours.
Figure 5. Vascular wall-resident multipotent stem cells (VW-MPSCs). VW-MPSC mobilization and differentiation in‐
to SMC may also be induced by signals released from, e.g., tumours, inflammation and hypoxia in tissue areas around
blood vessels contributing to morphogenesis of the new vessel wall. It is hypothesized that VW-MPSCs are the “first-
line” cells which were mobilized from their niche towards the tumour and activated to differentiate into pericytes and
SMCs, which in turn stabilize angiogenic blood vessels. The molecular analysis of these stabilizing wall cells could
yield new strategies for single-target genes, which could reduce the rate of drug-resistant tumours. Without mobiliza‐
tion from the niche VW-MPSCs express specific transcription factors at high levels. These genes suppress the expres‐
sion of SMC-specific genes in VW-MPSCs. This mechanism probably accounts for keeping the VW-MPSCs quiescent in
the adventitial niche. Tissue-resident MPSC and in particular VW-MPSCs, rather than circulating (BM-derived) multi‐
potent stem cells, represent the major source of pericytes and SMCs during tumour vascularization. These findings on
the origin of vascular-stabilizing pericytes and their function in tumour vascularization and remodelling provide a fur‐
ther basis for the design of novel strategies to improve anti-angiogenic therapies.
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